Tempest Therapeutics
PublicTempest Therapeutics is now publicly traded
The data on this page reflects Tempest Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Sep 15, 2026
Total Funding Raised
$9.5M
Company Overview
Tempest Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics and in vivo CAR-T cell therapies for oncology and autoimmune indications.
Sector
Biotech
AI Layer
Non-AI
Keywords
Tempest Therapeutics Comparables
Compare Tempest Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ethonova | 73% | |
| FGH BioTech, Inc. | 55% | |
| Euclises Pharmaceuticals | 49% |
Tempest Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Sep 15, 2026 | ||||
| Private Placement | Apr 3, 2026 |
Recent news
Latest coverage and updates
- partners_withSep 16, 2026
Tempest Therapeutics, Inc. partnered with Senlang on Sep 16th '26.
Tempest Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access